ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
2.060
-0.040 (-1.90%)
At close: Aug 10, 2026, 4:00 PM EDT
2.055
-0.005 (-0.24%)
After-hours: Aug 10, 2026, 7:34 PM EDT
ALX Oncology Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
284.85M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fulcrum Therapeutics | 80.00M |
| Bicycle Therapeutics | 61.21M |
| Zentalis Pharmaceuticals | 26.87M |
| Sol-Gel Technologies | 18.47M |
| Lineage Cell Therapeutics | 13.08M |
| Surrozen | 11.51M |
| InflaRx | -11.54K |
ALXO News
- 4 days ago - ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 days ago - ALX Oncology Holdings Earnings release: Q2 2026 - Filings
- 4 days ago - ALX Oncology Holdings Quarterly report: Q2 2026 - Filings
- 5 weeks ago - ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 5 weeks ago - ALX Oncology chairman Corey Goodman steps down, Scott Garland succeeds - TheFly
- 5 weeks ago - ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel - GlobeNewsWire
- 2 months ago - ALX Oncology Holdings Transcript: AGM 2026 - Transcripts
- 2 months ago - ALX Oncology Holdings Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts